Safracin B
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02219 |
| CAS | 87578-99-2 |
| Molecular Weight | 540.61 |
| Molecular Formula | C28H36N4O7 |
| Purity | ≥85% (HPLC) |
Online Inquiry
Description
Safracin B is a new antibiotic from the family of Safracin produced by Pseudomonas fluorescens A2-2. Safracin B exhibits broad spectrum antimicrobial and strong antitumor activities.
Specification
| Related CAS | 82029-27-4 |
| Synonyms | Antibiotic EM 5519; Antibiotic Y 16482α |
| IUPAC Name | (2S)-2-amino-N-[[(1S,2S,10R,12S,13R)-12,19-dihydroxy-7,18-dimethoxy-6,17,21-trimethyl-5,8-dioxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),16,18-pentaen-10-yl]methyl]propanamide |
| Canonical SMILES | CC1=CC2=C(C3C4CC5=C(C(N4C(C(C2)N3C)O)CNC(=O)C(C)N)C(=O)C(=C(C5=O)C)OC)C(=C1OC)O |
| InChI | InChI=1S/C28H36N4O7/c1-11-7-14-8-17-28(37)32-16(21(31(17)4)19(14)23(34)25(11)38-5)9-15-20(18(32)10-30-27(36)13(3)29)24(35)26(39-6)12(2)22(15)33/h7,13,16-18,21,28,34,37H,8-10,29H2,1-6H3,(H,30,36)/t13-,16-,17+,18-,21+,28-/m0/s1 |
| InChI Key | GKUZBRIJGIGFKC-XPXFATIHSA-N |
Properties
| Appearance | Yellow to Brown powder |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria; neoplastics (Tumor) |
| Boiling Point | 755.1°C at 760 mmHg |
| Melting Point | >260°C |
| Density | 1.41 g/cm3 |
Reference Reading
1. Biosynthesis of Tetrahydroisoquinoline Antibiotics
Li-Qiang Song, Man-Cheng Tang, Gong-Li Tang, Yue Zhang Curr Top Med Chem . 2016;16(15):1717-26. doi: 10.2174/1568026616666151012112329.
The tetrahydroisoquinoline (THIQ) alkaloids are naturally occurring antibiotics isolated from a variety of microorganisms and marine invertebrates. This family of natural products exhibit broad spectrum antimicrobial and strong antitumor activities, and the potency of clinical application has been validated by the marketing of ecteinascidin 743 (ET-743) as anticancer drug. In the past 20 years, the biosynthetic gene cluster of six THIQ antibiotics has been characterized including saframycin Mx1 from Myxococcus xanthus, safracin-B from Pseudomonas fluorescens, saframycin A, naphthyridinomycin, and quinocarcin from Streptomyces, as well as ET-743 from Ecteinascidia turbinata. This review gives a brief summary of the current status in understanding the molecular logic for the biosynthesis of these natural products, which provides new insights on the biosynthetic machinery involved in the nonribosomal peptide synthetase system. The proposal of the THIQ biosynthetic pathway not only shows nature's route to generate such complex molecules, but also set the stage to develop a different process for production of ET-743 by synthetic biology.
2. Characterization of the saframycin A gene cluster from Streptomyces lavendulae NRRL 11002 revealing a nonribosomal peptide synthetase system for assembling the unusual tetrapeptidyl skeleton in an iterative manner
Gong-Li Tang, Wei Ding, Jie Song, Wei Deng, Qun-Fei Zhao, Chao Peng, Wei-Wen Song, Lei Li, Wen Liu J Bacteriol . 2008 Jan;190(1):251-63. doi: 10.1128/JB.00826-07.
Saframycin A (SFM-A), produced by Streptomyces lavendulae NRRL 11002, belongs to the tetrahydroisoquinoline family of antibiotics, and its core is structurally similar to the core of ecteinascidin 743, which is a highly potent antitumor drug isolated from a marine tunicate. In this study, the biosynthetic gene cluster for SFM-A was cloned and localized to a 62-kb contiguous DNA region. Sequence analysis revealed 30 genes that constitute the SFM-A gene cluster, encoding an unusual nonribosomal peptide synthetase (NRPS) system and tailoring enzymes and regulatory and resistance proteins. The results of substrate prediction and in vitro characterization of the adenylation specificities of this NRPS system support the hypothesis that the last module acts in an iterative manner to form a tetrapeptidyl intermediate and that the colinearity rule does not apply. Although this mechanism is different from those proposed for the SFM-A analogs SFM-Mx1 and safracin B (SAC-B), based on the high similarity of these systems, it is likely they share a common mechanism of biosynthesis as we describe here. Construction of the biosynthetic pathway of SFM-Y3, an aminated SFM-A, was achieved in the SAC-B producer (Pseudomonas fluorescens). These findings not only shed new insight on tetrahydroisoquinoline biosynthesis but also demonstrate the feasibility of engineering microorganisms to generate structurally more complex and biologically more active analogs by combinatorial biosynthesis.
3. Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation
H Idemoto, T Asao, F Hirayama, K Iwao, T Munakata, K Yamamoto, Y Ikeda J Antibiot (Tokyo) . 1983 Oct;36(10):1279-83. doi: 10.7164/antibiotics.36.1279.
Safracins, new antibiotics with a novel skeleton, were discovered in a culture broth of Pseudomonas sp. The producing organism has been identified as Pseudomonas fluorescens. Safracins A and B were isolated by ethyl acetate extraction and chromatography on silica gel.
Recommended Products
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
